[1]Teufel F, Orgutsova K, Genitsaridi I, et al. Global, Regional, and national estimates of undiagnosed diabetes in adults: findings from the 2025 IDF diabetes Atlas[J]. Diabetes Care, 2026, 49(3): 490-496.
[2]Du J P, Tang Y, Qin Y C, et al. Investigation and future trend prediction of disease burden of chronic kidney disease due to diabetes mellitus type 2 globally and in China from 1990 to 2021[J]. J Diabetes Investig, 2026, 17(2): 256-266.
[3]Martinez Leon V, Hilburg R, Susztak K. Mechanisms of diabetic kidney disease and established and emerging treatments[J]. Nat Rev Endocrinol, 2026, 22(1): 21-35.
[4]李佳, 刘心悦, 时佳, 等. 早发2型糖尿病肾脏损伤的危险因素分析[J]. 实用医学杂志, 2026, 42(1): 87-93.
[5]Bergman R N, Stefanovski D, Buchanan T A, et al. A better index of body adiposity[J]. Obesity, 2011, 19(5): 1083-1089.
[6]Lam B C C, Koh G C H, Chen C, et al. Body adiposity index and percentage of body fat in an Asian population: a comparative study[J]. Obes Facts, 2023, 16(1): 1-11.
[7]Al-Samerria S, Radovick S. IGF-1 signaling in obesity and metabolic dysfunction: an update 2026[J]. Int J Mol Sci, 2026, 27(5): 1892.
[8]Liew A, Bavanandan S, Hao Chuanming, et al. Executive summary of the Asian pacific society of nephrology clinical practice guideline on diabetic kidney disease-2025 update[J]. Nephrology, 2025, 30(5): e70031.
[9]Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease[J]. Kidney Int, 2024, 105(S4): S117-S314.
[10]《糖尿病肾脏病早期筛查与管理专家共识》编写组. 糖尿病肾脏病早期筛查与管理专家共识(2025版)[J]. 中华糖尿病杂志, 2025, 17(7): 786-800.
[11]Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease[J]. Kidney Int Suppl, 102(S5): S1-S127.
[12]American Diabetes Association. (ADA). Standards of medical care in diabetes-2024[J]. Diabetes Care, 2024, 47(S1): S1-S264.
[13]中华医学会内分泌学分会. 肥胖患者的长期体重管理及药物临床应用指南(2024版)[J]. 中华内分泌代谢杂志, 2024, 40(7): 545-564.
[14]Inker L A, Eneanya N D, Coresh J, et al. New creatinine- and cystatin C-based equations to estimate GFR without race[J]. N Engl J Med, 2021, 385(19): 1737-1749.
[15]Ma J, Hao M, Yao J, et al. Association between life course adiposity and diabetic microvascular complications: a univariable and multivariable Mendelian randomization study[J]. Medicine, 2026, 105(14): e48247.
[16]Assani M Z, Novac M B, Dijmrescu A L, et al. Potential association between atherogenic coefficient, prognostic nutritional index, and various obesity indices in diabetic nephropathy[J]. Nutrients, 2025, 17(8): 1339.
[17]Spinoza E D, Fonte F K, Carvalho V A, et al. Body adiposity index as a predictor of body fat in an oldest old and Independent cohort of Brazilian older adults[J]. Ann Geriatr Med Res, 2024, 28(3): 284-290.
[18]Habib R, Mashhadi S F, Javed A, et al. Comparison of body adiposity index and body mass index for assessment of body fat percentage among office workers: a validation study[J]. Pak J Med Sci, 2025, 41(6): 1677-1682.
[19]Zhang W, Liu Y. The obesity-related indices are useful for predicting diabetic nephropathy in patients with type 2 diabetes mellitus: a retrospective cohort study of NHANES[J]. Endocrinol Diabetes Metab, 2025, 8(5): e70087.
[20]杨正芳, 张春虹, 徐静, 等. GH/IGF-1轴与成人2型糖尿病肾病相关性分析[J]. 西安交通大学学报: 医学版, 2025, 46(6): 960-965.
[21]Díaz Tocados J M, Pérez Gómez A, Diego Domínguez Coral J, et al. The multiple functions of insulin-like growth factor 1 in kidney disease[J]. Nefrologia, 2025, 45(7): 501337.
[22]Mohebi R, Liu Yuxi, Hansen M K, et al. Insulin growth factor axis and cardio-renal risk in diabetic kidney disease: an analysis from the CREDENCE trial[J]. Cardiovasc Diabetol, 2023, 22(1): 176.
[23]Banoth B, Raviraj S, Pasupulati A K. Human growth hormone-induced mitotic maladaptation in podocytes and implications in diabetic kidney disease[J]. J Neuroendocrinol, 2026, 38(2): e70122.
[24]American Diabetes Association Professional Practice Committee. 6. Glycemic goals and hypoglycemia: standards of care in diabetes-2025[J]. Diabetes Care, 2025, 48(1 Suppl 1): S128-S145.
[25]Ceriello A, Colagiuri S. IDF global clinical practice recommendations for managing type 2 diabetes -2025[J]. Diabetes Res Clin Pract, 2025, 222(S1): 112152.
[26]Guo J B, Liu C, Wang Y F, et al. Dose-response association of diabetic kidney disease with routine clinical parameters in patients with type 2 diabetes mellitus: a systematic review and meta-analysis[J]. EClinicalMedicine, 2024, 69: 102482.[27]Wang S H, Song S N, Gao J X, et al. Glycated haemoglobin variability and risk of renal function decline in type 2 diabetes mellitus: An updated systematic review and meta-analysis[J]. Diabetes Obes Metab, 2024, 26(11): 5167-5182.
|